CD61 Platelet Disorder Test | Lahalak Platform
A specialized diagnostic package evaluating platelet disorders and metastatic cancers, providing vital information for the effective treatment of bleeding or clotting conditions.
Scientific name: Immunohistochemistry (IHC): CD61
This diagnostic package, based on immunohistochemistry, includes the examination of a range of markers related to platelet formation and myelogenous origin. The package primarily involves the examination of CD61 (glycoprotein IIIa), a component of the GPIIb/IIIa complex found on the surface of platelets and megakaryocytes, as well as essential comp...
Service type
Laboratory test (Tumor Markers)
Duration
10-15 minutes
Fasting
Fasting is not required
Included Services
- Testing for the qualitative markers of platelets and nuclei: CD61 and CD42b.
- A broader myeloid marker test (CD41) was performed to confirm the myeloid lineage.
- Examination of the epithelial marker (Cytokeratin) to rule out a cancerous origin when evaluating metastases.
- Consultation for interpretation of the overall results with a pathologist specializing in blood diseases and bone marrow tumors.
Medical Service Information
Conditions & Notices
- It requires the submission of a complete tissue block (paraffin block) from a bone marrow biopsy sample (Trephine biopsy).
- It is necessary to attach the initial pathology report, the results of the complete blood count (CBC), and the detailed clinical history.
- The patient does not need to fast, as the sample is tissue-based.
- The completion time ranges from 5 to 10 working days.
Medical services you might also like
